Last reviewed · How we verify
NCT05537519
Phage Therapy for the Treatment of Urinary Tract Infection
Phase 1, PHASE2 trial testing Phage Therapy in Recurrent Urinary Tract Infection in 1 participant. Status unknown.
28 July 2023
Quick facts
| Lead sponsor | Unity Health Toronto |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 1 May 2023 |
| Primary completion | 28 July 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Phage Therapy — full drug profile →
Conditions studied
- Recurrent Urinary Tract Infection — all drugs for Recurrent Urinary Tract Infection →
Sponsor
Unity Health Toronto — full company profile →
Who can join
18 and older, female only, with Recurrent Urinary Tract Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urinary tract infection with serious long-term effects. This study will follow a minimally invasive phage therapy approach consisting of oral, topical (opening of the urethra) and bladder installations of a 3-phage cocktail comprised of HP3, HP3.1 and ES19.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.
Karn SL, Gangwar M, Kumar R, Bhartiya SK, et al · · 2023 · cited 12× · PMID 37928478 · DOI 10.3389/fmed.2023.1209782 -
Emerging antimicrobial therapies for Gram-negative infections in human clinical use.
Hickson SM, Ledger EL, Wells TJ. · · 2025 · cited 11× · PMID 40016340 · DOI 10.1038/s44259-025-00087-2 -
Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.
Taati Moghadam M, Mohebi S, Sheikhi R, Hasannejad-Bibalan M, et al · · 2025 · cited 4× · PMID 40661138 · DOI 10.1002/mco2.70280 -
Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.
Morgan CJ, Atkins H, Wolfe AJ, Brubaker L, et al · · 2025 · cited 3× · PMID 40358692 · DOI 10.1007/s00192-025-06136-8 -
Antimicrobial Resistance: The Answers.
Millar BC, Cates MJ, Torrisi MS, Round AJ, et al · · 2026 · PMID 41727556 · DOI 10.3389/bjbs.2026.15559 -
A Century of Bacteriophages: Insights, Applications, and Current Utilization.
Dkhili S, Ribeiro M, Slama KB. · · 2025 · PMID 41301576 · DOI 10.3390/antibiotics14111080 -
Is a Bacteriophage Approach for Musculoskeletal Infection Management an Alternative to Conventional Therapy?
Eschweiler J, Fischer C, Migliorini F, Greven J, et al · · 2025 · PMID 41157207 · DOI 10.3390/life15101534
Verify or expand the search:
- PubMed search for NCT05537519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Phage Therapy
Trials testing the same drug.
- NCT04636554 — Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Se · no longer available
Other recruiting trials for Recurrent Urinary Tract Infection
Currently open trials in the same condition.
- NCT06940622 — A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections · NA · recruiting
- NCT06124820 — RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections · NA · active not recruiting
- NCT06050148 — Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections · Phase 2, PHASE3 · recruiting
- NCT05553652 — The Effect of ASTARTE™ on Recurrent Urinary Tract Infection · NA · recruiting
- NCT04807894 — Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo · Phase 4 · recruiting
Other Unity Health Toronto trials
Trials by the same sponsor.
- NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
- NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
- NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
- NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
- NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05537519 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
- Last refreshed: 26 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05537519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing